 August
12, 2015 Canaccord
Genuity 35th Annual Growth Conference Exhibit 99.1 |
 2 Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements about our plans to develop and commercialize our product candidates, our planned clinical trials for KP201/APAP and our other prodrug product candidates, the timing of and our ability to obtain and maintain regulatory approvals for our product candidates, including expectations about our ability to use the 505(b)(2) pathway and expedited FDA review, the clinical utility of our product candidates and our intellectual property position. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this presentation represent our views as of the date of this presentation. These and other risks concerning our business are described in additional detail in our Registration Statement on Form S-1 (Registration No. 333-202660) declared effective April 15, 2015, and our other Periodic and Current Reports filed with the Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Any information in this presentation provided by IMS Health Incorporated (IMS) is an estimate derived from the use of information under license from the following IMS Health information service: IMS National Sales Perspectives and NPA Audits, in each case, for the period of January 2011 to September 2014. IMS expressly reserves all rights, including rights of copying, distribution and republication. |
 3 KemPharm Overview • Specialty pharmaceutical company discovering and developing novel prodrugs • Leverage LAT Platform Technology to improve
the attributes of approved drugs in large markets
o 505(b)(2) pathway reduces risk and
expense o
Composition-of-matter patent protection • KP201/APAP has the potential to be the
first FDA approved abuse- deterrent IR hydrocodone/APAP product (NDA submission in 2H 2015) o IR hydrocodone is the highest
prescribed opioid in the U.S. •
Pipeline of product candidates in pain, ADHD and other CNS disorders |
 4 Management Team Travis C. Mickle, PhD President and CEO Gordon K. Johnson CBO Tracy M. Woody CCO R. LaDuane Clifton CFO Sven Guenther, PhD EVP of R&D |
 5 Ligand Activated Therapy (LAT) Platform Technology 1) Select FDA-approved and widely prescribed drug for improvement 2) Chemically modify using a ligand to create a prodrug o Ligands – GRAS or demonstrated to be safe o Prodrugs generate composition-based patents 3) Following ingestion, normal human metabolic processes cleave the ligand and release the active drug • Proprietary to KemPharm and is applicable across therapeutic areas
• Amenable to both immediate and extended release formulations
Approved Drug with
Sub-Optimal
Properties
Prodrug with Improved Attributes Cleaved Drug through Human Metabolic Process Ligand LAT LAT LAT |
 6 Pipeline of Multiple Product Candidates Selected KemPharm Prodrug Product Candidates Indication / Parent Drug Product Candidate Development Status Key Milestone Pain Hydrocodone (IR) KP201/APAP Clinical Trials NDA Filing – 2H 2015 Hydromorphone (ER) KP511/ER Preclinical Human POC Data – 2016 Oxycodone (ER) KP606/ER Preclinical Human POC Data – 2017 ADHD Methylphenidate (controlled release) KP415 Preclinical Human POC Data – 2016 Multiple CNS Disorders Quetiapine KP303 Preclinical Preclinical Development Multiple Other Compounds in Pre-Discovery Stage |
 7 Advancing Opioid Abuse-Deterrent Technology High Tamper Resistance KemPharm’s Molecular Based Abuse-Deterrent Technology Crushing or Physical Manipulation Extraction Chemical Hydrolysis Neutralization and/or Isolation Many Formulation- Based Abuse-Deterrent Opioids Crushing or Physical Manipulation Extraction Traditional Opioids No Tamper Resistance Number and complexity of steps required to access abusable opioids |
 8 Opioid Abuse-Deterrent Landscape KemPharm Prodrugs OxyContin TARGINIQ EMBEDA Hysingla Parent Drug Multiple IR/ER Opioids ER Oxycodone ER Oxycodone ER Morphine ER Hydrocodone Resists Physical Tampering Resists Non-Oral Abuse Molecular-Based Deterrence x x x x Prevents Common Solvent Extraction x x x x
Potentially Prevents Oral Abuse
x x x x
|
 9 Treatment of Acute Moderate to Moderately Severe Pain KP201/APAP Overview |
 10 KP201/APAP Product Features Molecular-Based Abuse-Deterrent Technology Composition-of-Matter Patent Protection Until 2031 No Generic Equivalent Product (Benzhydrocodone) Prodrug composed of hydrocodone and a generally regarded as safe (GRAS) ligand Convenient Dosing Planned NDA submission in 2H 2015 with priority review anticipated Successfully completed bioequivalence trial in humans |
 11 Bioequivalence Study KP201.102 (KP201/APAP vs. Norco ® ) Hydrocodone/Hydromorphone Acetaminophen C max AUC 0-t AUC inf T max 87% 94% 94% 102% 92% 100% 90% 120% C max AUC 0-t AUC inf T max APAP 92% 102% 99% 98% Note: HC refers to hydrocodone. HM refers to hydromorphone, the active metabolite of hydrocodone. 0 50 100 150 200 250 300 350 400 450 500 0 4 8 12 16 20 24 Time [hours] 0 5,000 10,000 15,000 20,000 1 ×7.5/325 mg
Norco (HC)
1 ×6.67/325
mg KP201/APAP (HC)
1 ×7.5/325 mg
Norco (HM)
1 ×6.67/325
mg KP201/APAP (HM)
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 0 4 8 12 16 20 24 Time [hours] 1 ×7.5/325 mg
Norco 1
×6.67/325 mg
KP201/APAP Hydrocodone
Hydromorphone |
 12 KP201/APAP Tamper Resistant Properties – In Vitro Studies • Extraction of API (KP201) only yields inactive prodrug • Hydrocodone not released through: o Physical manipulation (e.g., grinding) o Common solvent extraction (e.g., “alcohol dose dumping”, “cold water
extraction”) • KP201 is chemically stable under commonly applied “extraction methods”
• Hydrolysis under very harsh conditions is not practical o KP201 partially hydrolyzes under highly basic/acidic conditions o Poor solubility in blood, water and other solvents render it unsuitable for IV administration |
 13 KP201 Solvent Hydrolysis Studies Solvent % Release of Hydrocodone Ambient Temperature At Boiling Point 0.5 hours 1 hour 4 hours 0.5 hours 1 hour 4 hours Water 0 0 0 0 0 0 Ethanol 0 0 0 0 0 0 Methanol 0 0 0 0 0 0 Acetone 0 0 0 0 0 0 Ethyl acetate 0 0 0 0 0 0 Toluene 0 0 0 0 0 0 Xylene 0 0 0 0 0 0 Tetrahydrofuran 0 0 0 0 0 0 Methy ethyl ketone 0 0 0 0 0 0 Octane 0 0 0 0 0 0 Petrol ether 0 0 0 0 0 0 Preliminary results suggest that KP201 remains intact and does not hydrolyze or
break down into its components in commonly available solvents
|
 14 KP201 Abuse-Deterrent Properties in Rat Studies Note: HC·BT refers to hydrocodone bitartrate. Intranasal Intravenous 0 1,000 2,000 3,000 4,000 0.0 0.2 0.4 0.6 0.8 1.0 Time [hours] HC·BT (25.5 mg/kg HC eq.) KP201 (0.2 mg/kg HC eq.) 0 100 200 300 400 500 0.0 0.2 0.4 0.6 0.8 1.0 Time [hours] HC·BT (2.0 mg/kg HC eq.) KP201 (2.0 mg/kg HC eq.) |
 15 Recently Completed KP201.A01 Human Abuse Liability Trial • Oral Human Abuse Liability Trial o Compared the drug likability, exposure levels and safety of KP201/APAP compared to Norco after oral administration o Single-center, randomized, double-blind, active- and placebo-controlled crossover trial (62 subjects completed the study) • Positive data announced on June 11, 2015 o Lower exposure to hydrocodone at the highest dose levels o Lower incidence of hypoxia across the same dosage levels, suggestive of the potential for improved safety o Liking data was similar at each equivalent dose level, as expected |
 16 Ongoing Human Abuse Liability and PK Trials • Intranasal Human Abuse Liability Trial o Assesses the drug likability, exposure levels and safety of KP201/APAP compared to Norco after crushing and intranasal administration o Single-center, randomized, double-blind trial (n=40) o Data in 3Q 2015 • Intranasal KP201 (API) PK Trial o Assesses the drug exposure levels of KP201 (API) compared to hydrocodone bitartrate after intranasal administration o Single-center, randomized, double-blind trial (n=24) o Data in 3Q 2015 |
 17 KP201/APAP Potential Abuse-Deterrent Label Claims • The FDA outlines 3 types of studies that may translate into 4 categories of label claims • KemPharm’s abuse liability program is consistent with the FDA Guidance: o Extraction/hydrolysis study o Oral abuse liability trial (with pharmacokinetics) o Intranasal abuse liability trial (with pharmacokinetics) • KP201/APAP will be compared with Norco ® in all studies • Studies will be completed before filing of NDA • If data is positive, label may include claims for up to 3 categories at approval FDA Guidance 1. Laboratory manipulation and extraction studies (Category 1)
2.
Pharmacokinetic studies (Category 2)
3.
Clinical abuse potential studies (Category
3) There are four general categories of claims available to describe the
potential abuse-deterrent properties of a product. Depending
on product and study data, a combination of categories can
be included in the label claims. The FDA Guidance lists the following theoretical examples: • Category 1: In vitro data demonstrate the product has physical and chemical
properties that are expected to deter intravenous
abuse. 1
• Category 1 and 2: In vitro data demonstrate that the product has physical and chemical properties that are expected to deter oral, nasal and intravenous abuse.
1
• Category 2 and 3: Pharmacokinetic and clinical abuse potential studies indicate that the
product has properties that are expected to deter abuse
via the oral, intranasal and intravenous
routes. 1
• Category 4: Data demonstrated a reduction in the abuse of the product in
the community
1
1
Abuse of the product is still possible by other
routes |
 18 Large Market Opportunity • Hydrocodone is associated with more drug abuse and diversion than any other licit or illicit opioid (1) • IR hydrocodone in combination with acetaminophen is the most frequently prescribed opioid in the U.S. (2) o IR hydrocodone/APAP products accounted for 127.4 million prescriptions in the U.S. in 2013 (2) o Assuming 14 days therapy prescribed and QID dosing, 127.4 million prescriptions translates into over 7 billion tablets per year (1) DEA website. (2) IMS Health Incorporated. |
 19 KP201/APAP Commercial Strategy • Potential global / U.S.-based deal targeting large prescriber base, including primary care physicians • Utilize contract sales force(s) Collaboration • Specialist sales force targeting pain thought leaders, pain management specialists and high prescribing health care professionals • License international commercial rights to one or more collaborators Specialist U.S. Sales Force KemPharm has many potential avenues to commercialize KP201/APAP, including but not limited to, a collaboration or establishing a specialist U.S. sales force |
 20 State Legislative Initiatives AL AL AZ AZ AR AR CA CA CO** CO** FL FL GA GA ID ID IL IL IN IN IA IA KS KS KY KY LA LA ME ME MA MA MI MI MN MN MS MS MO MO MT MT NE NE NV NV NH* NH* NM* NM* NY NY NC NC ND ND OH OH OK OK OR OR PA PA SC SC SD SD TN** TN** TX TX UT** UT** VT VT VA* VA* WA WA WV* WV* WI WI WY WY CT CT DE DE MD MD NJ NJ RI RI Passed by one or both Houses Introduced Passed & signed by Gov. To be filed Enacted into law * Bill would require a study of AD inclusion on formularies ** Bill has been converted or deferred to a study Source: Presentation by Dan Cohen, CBI’s Abuse Deterrent Formulations Conference, May 19-20, 2015, “Working with
Policymakers and Payers to Improve the Incentives for ADFs”
and company data. |
 21 KP201/APAP Milestones Human Bioequivalence Preclinical Abuse Deterrence / Tamper Resistance Oral Human Abuse Liability Trial Intranasal Human Abuse Liability Trial 3Q 2015 Intranasal PK Trial 3Q 2015 NDA Submission 2H 2015 NDA Approval (with priority review) As Early As Mid-2016 DEA Scheduling and Product Launch As Early As 2017 |
 22 Treatment of Moderate to Severe Pain KP511/ER Overview |
 23 KP511/ER Product Overview • KP511/ER is an ER formulation of KP511, a prodrug of hydromorphone • IR bioequivalent release of hydromorphone demonstrated in rats • Potential valuable properties based on preclinical data o Significantly reduced IN and IV bioavailability (abuse deterrence) o Highly tamper resistant o Limited oral bioavailability at high doses (overdose protection) • Composition-based patent expires in 2032 • Potential for POC data in 2016 and utilization of the 505(b)(2) regulatory pathway |
 24 KP511/ER Reduced Abuse Potential Intranasal PK Curves Intravenous PK Curves Note: HM refers to hydromorphone hydrochloride. Studies conducted in rats. • 2.0 mg/kg (hydromorphone eq.) • Average data from 2 studies (N=10) • %-AUC = 25% • %-C max = 22% • 0.2 mg/kg (hydromorphone eq.) • 1 study (N=5) • %-AUC = 5% • %-C max = 6% 0 200 400 600 800 1,000 1,200 0 0.2 0.4 0.6 0.8 1 Time [h] HM (compiled) KP511 (compiled) 0 10 20 30 40 50 60 0 0.5 1 1.5 2 Time [h] HM KP511 |
 25 KP511/ER Potential Oral Overdose Protection AUC Note: HM refers to hydromorphone hydrochloride. Studies conducted in rats. 0 500 1,000 1,500 2,000 2,500 3,000 3,500 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 Dose [mg/kg HM] HM·HCl extrapolated HM·HCl (HM) KP511 (HM) 0 5 10 15 20 25 30 35 0 1 2 3 4 Time [h] |
 26 Treatment for ADHD KP415 Overview |
 27 KP415 Overview • Prodrug of methylphenidate • Branded formulations of methylphenidate (Concerta, Focalin and Ritalin) accounted for sales of $1.1 billion in 2014 (1) • Potential features and benefits o Controlled release methylphenidate o Reduced abuse potential o Suitable for more patient compliant dosage form Highly water soluble Oral thin film, orally dissolving tablet, liquid, chewable • Potential for POC data in 2016 (1) Public filings. |
 28 KemPharm Expected News Flow Product Event Date KP201/APAP Intranasal Human Abuse Liability Trial – Clinical Results 3Q 2015 KP201 (API) Intranasal PK Trial – Clinical Results 3Q 2015 KP201/APAP NDA Submission 2H 2015 KP201/APAP NDA Approval (Priority Review) As Early As Mid-2016 KP201/APAP DEA Scheduling and Product Launch As Early As 2017 KP511/ER Human POC 2016 KP415 Human POC 2016 KP606/ER Human POC 2017 |
 29 1Q 2015 Update • Cash of $10.3 million as of March 31, 2015 • Net proceeds from IPO in April/May 2015 of $59.9 million, net of underwriting discounts and commissions • 1Q 2015 net loss was $6.0 million vs. $1.9 million for 1Q 2014 o Increase in net loss year-over-year primarily due to IPO expenses and KP201/APAP R&D • $35 million available under the $60 million Deerfield facility: o $10 million optionally available upon NDA acceptance o $25 million optionally available upon NDA approval |
 For
additional information please contact: Gordon K. “Rusty”
Johnson rjohnson@kempharm.com
319-665-2575 |